In today's Pharmaceutical Executive Daily, Angelini Pharma announces a $4.1 billion agreement to acquire Catalyst ...

Madrigal Pharmaceuticals entered an exclusive global license agreement with Arrowhead Pharmaceuticals for ARO-PNPLA3, a ...

Consideration is set at $31.50 per Catalyst share in cash, implying an equity value above $4.1 billion and a 21% premium to ...

An expected surge in generic GLP-1s is anticipated to reshape not only pharmaceutical pricing and access but also the global MedTech ecosystem supporting drug delivery. In today's Pharmaceutical ...

Pharmaceutical Executive: What elements is the conversation about bringing pharma manufacturing home missing? Charlie Lyon: ...

FDA cleared the first agent with an NMDA/sigma-1–based mechanism specifically for agitation in Alzheimer’s disease dementia, ...

In March of this year, the API Innovation Center released its whitepaper titled, “From Fragility to Resilience: Aligning ...

Natalie de Graaf is VP and GM of Data, AI and ML; Solutions for Health and National Security at the API Innovation Center. Natalie de Graaf, from the API Innovation Center, discusses a recent ...

Pharmaceutical Executive spoke with Aradigm Health CEO Will Shrank at the Asembia ASX26 Summit in Las Vegas. During the conversation, he explained the issues the payers face with cell & gene therapies ...

Ultimately, making RWE actionable means shortening the gap between insight and application. When data is reliable, complete, and easy to use, it can support better decisions, faster adoption of new ...

ASPENOVA randomizes Cyclin E1-positive PROC to azenosertib versus paclitaxel, PLD, gemcitabine, or topotecan, reflecting current NCCN sequential single-agent practice. PFS is the primary endpoint, ...

UCB enters agreement to acquire Candid Therapeutics in a deal worth up to $2.2 billion, adding BCMA-targeting T-cell engager ...